Table 4. Characteristics of patients with metastasectomy.
| Patient | Metastasectomy (location and surgical techniques) | Intention of metastasectomy | Tumour burden left after metastasectomy (other sites) | Time to tumour progression after complete metastasectomy | KPS | Risk group | Time between diagnosis and metastasectomy (months) | Time between metastasectomy and immunotherapy (months) |
|---|---|---|---|---|---|---|---|---|
| 1 | Bone (hip: resection and reconstruction) | Fracture, pain control | Bone | 90 | Medium | 60.79 | 1.55 | |
| 2 | Bone (curretage and vertebroplasty) | Fracture, pain control | Bone | 90 | Medium | 15.63 | 2.01 | |
| 3 | Bone (humerus: curretage and plate osteosynthesis) | Fracture, pain control | Liver, lung, mediastinal lymph Nodes | 100 | High | 0.59 | 2.6 | |
| 4 | Bone (2 curretages and vertebroplasties) | Pain control | Liver | 100 | Medium | 1.61 | 0.86 | |
| 5 | Bone (humerus: curretage and plate osteosynthesis) | Fracture, pain control | Liver, lung | 100 | Medium | 13.2 | −11.2 | |
| 6 | Bone (curretage and vertebroplasty) | Pain control | Liver | 100 | Medium | 98.52 | 1.84 | |
| 7 | Lung (segment resection), bone (hip: resection and reconstruction) | Tumour reduction | No | 4.3 | 90 | Low | 0 | 0.56 |
| 8 | Lung (segment resection) | Tumour reduction | No | 9.4 | 100 | High | 267.40 | 0.92 |
| 9 | Pancreas (whipple operation) | Tumour reduction | No | 46 | 100 | Medium | 0 | 46.25 |
| 10 | Bone (curretage and vertebroplasty) | Pain control | Lung | 100 | Medium | 16.41 | 3.05 | |
| 11 | Bone (humerus: curretage and plate osteosynthesis) | Fracture, pain control | Bone | 100 | High | 65.53 | 1.15 | |
| 12 | Bone (femur: curretage and osteosynthesis) | Fracture, pain control | Lung | 90 | High | 0 | 2.1 | |
| 13 | Lung (segment resection) | Tumour reduction/ othersa | Abdominal lymph nodes | 100 | High | 0 | 1.74 | |
| 14 | Bone (femur, acetabulum: curretage and osteosynthesis) | Fracture, pain control | Lung | 90 | High | 51.09 | 3.18 | |
| 15 | CNS (excision), lung (segment resection) | Vital indication | No | 2 | 100 | Medium | 33.78 | 2.47 |
| 16 | Local recurrence (tumour debulking) | Pain control | No | 6 | 100 | High | 93.16 | 12.01 |
| 17 | Bone (curretage and vertebroplasty) | Fracture, pain control | Bone | 100 | Medium | 12.93 | −13.08 | |
| 18 | Bone (hip: excision and reconstruction) | Fracture, pain control | Adrenal | 80 | High | 0 | 2.3 | |
| 19 | CNS (excision) | Vital indication | Lung, bone | 100 | High | 35.13 | 14.97 | |
| 20 | Local recurrence (tumour debulking) | Pain control | Regional tumour mass | 100 | Medium | 48.06 | −28.32 | |
| 21 | Bone (femur: curretage and osteosynthesis) | Fracture, pain control | Bone | 100 | Low | 0 | 2.92 | |
| 22 | Lung (excision of pleural metastasis) | Tumour reduction | No | 50.2 | 100 | Medium | 96.12 | 53.91 |
| 23 | Bone (hip: excision and reconstruction) | Fracture, pain control | Lung | 80 | High | 0.95 | −0.33 | |
| 24 | CNS (excision) | Tumour reduction | Lung | 100 | High | 110.13 | −4.38 | |
| 25 | Bone (hip: excision and reconstruction) | Fracture, pain control | Lung | 100 | High | 0.49 | 0.72 | |
| 26 | Lung (segment resection) | Tumour reduction | No | 9.2 | 100 | High | 6.05 | −5.66 |
| 27 | Local recurrence (tumour debulking) | Pain control | Lung | 100 | Low | 121.12 | 23.52 | |
| 28 | CNS (excision) | Vital indication | Lung | 100 | High | 46.05 | −22.83 | |
| 29 | Bone (femur: curretage and osteosynthesis) | Fracture, pain control | Bone | 100 | High | −5.23 | 6.64 | |
| 30 | Bone (femur: curretage and osteosynthesis) | Fracture, pain control | Lung | 80 | Medium | −7.04 | 18.75 | |
| 31 | Lung (segment resection) | Tumour reduction/ othersb | Lung | 100 | High | 90.16 | −14.97 | |
| 32 | Bone (curretage and vertebroplasty) | Pain control | Bone | 90 | High | 60.10 | 24.21 | |
| 33 | Bone (hip: excision and reconstruction) | Pain control | Lung | 100 | High | 127.80 | 4.38 | |
| 34 | Bone (hip: excision and reconstruction) | Pain control | Lung | 90 | High | 73.09 | −7.27 | |
| 35 | Lung (segment resection) | Tumour reduction/ othersa | Liver | 90 | High | 0 | 2.37 | |
| 36 | Bone (hip: excision and reconstruction) | Fracture, pain control | Bone | 90 | High | 0 | 2.56 | |
| 37 | Local recurrence | Pain control | Bone | 100 | High | 132.24 | 1.61 | |
| 38 | Lung (segment resection) | Tumour reduction/othersa | Bone, lung | 90 | Medium | −0.89 | 1.35 | |
| 39 | Bone (humerus: curretage and plate osteosynthesis) | Fracture, pain control | Liver | 100 | Medium | −4.38 | 6.35 | |
| 40 | Bone (femur: curretage and osteosynthesis) | Fracture, pain control | Lung | 100 | Medium | −0.43 | 1.88 | |
| 41 | Bone (curretage and vertebroplasty) | Pain control | Liver | 80 | Medium | 33.95 | 19.11 | |
| 42 | Bone (hip: excision and reconstruction), lung (segment resection) | Tumour reduction, pain control | No | 7 | 100 | High | 120.86 | 7.53 |
| 43 | Local recurrence (tumour debulking), lung (lobectomy) | Tumour reduction | No | 14.5 | 100 | High | 102.01 | −5.8 |
| Total | Bone: 27.3% Lung: 11.1% CNS: 4% Local recurrence: 5% Pancreatic lesion: 1% Metastasectomy twice: 5% Total: 43.3% | Pain control/fracture: 65.1% Vital indication: 9.3% Tumour reduction: 27% | Other sites left: 79% NED: 21% | Median: 9.2 Months range: 2–50.2 | >80%: 90.7% ⩽80%: 9.3% | Low risk: 7% Medium risk: 37.2% High risk: 55.8% | Median time: 6 months after diagnosis Range: 1–267 months | Median time: 2 months after metastasectomy Range: 28 months prior – 54 months after metastasectomy |
CNS=central nervous system; KPS=Karnofsky performance status.
a
Metastases to other sites were diagnosed only a few days after metastasectomy.
b
Unexpected incomplete resection of the metastases.